Fit Biotech Oy, of Tampere, Finland, said that, under its convertible note and warrant programs established with Alpha Blue Ocean (ABO), the company's board has approved ABO's request to convert €30,000 (US$34,984) worth of convertible capital notes into the company's K shares. It says it will transfer 75 million new K shares to ABO.